We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease

By LabMedica International staff writers
Posted on 20 Nov 2026

Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. More...

Blood-based testing could help identify disease-associated signals from small sample volumes, but exosome detection can be complicated by interference from other molecules in the blood. To overcome this limitation, researchers have developed an experimental diagnostic platform that screens for all four diseases using 10 microliters of blood in about one hour.

Researchers at the University of Notre Dame developed the patent-pending diagnostic platform using immunojanus particles, tiny spheres with two chemically distinct halves. One side is coated with antibodies that bind disease-associated targets, while the other is fluorescent and provides a detectable signal. The platform is designed to identify exosomes in blood that carry proteins associated with disease.

To perform the test, blood is diluted with saline and mixed with the immunojanus particles for 10 to 60 minutes. As the particles disperse through the sample, their antibodies bind to disease-specific proteins on the surface of exosomes. The sample is then examined under a microscope, where proprietary software analyzes the particles’ Brownian motion to determine whether a disease-associated marker is present.

The platform was evaluated in a blind setting using 87 plasma samples from blood draws from healthy individuals and patients with one of the four diseases. It showed 90% to 99% accuracy for detecting the presence or absence of each disease type. The study, “Rapid and sensitive detection of cancer-derived small extracellular vesicles using Janus particles,” was published in Nature Biomedical Engineering

The method is described as fast and low-cost, and as more accurate than the leading exosome detection technology. Its design addresses interference by combining sensitivity to single exosome binding with selectivity against other small molecules. “We believe that if we can screen these diseases earlier, then patients may have a better chance at surviving,” said Hsueh-Chia Chang, the Bayer Corporation professor of engineering in the Department of Chemical and Biomolecular Engineering at Notre Dame. 

“We had to overcome the interference issue, and immunojanus particles can because they are both sensitive and selective. Sensitive because we can detect a single exosome on an immunojanus particle from the blinking frequency, and selective because other small molecules do not produce a signal,” added Chang.

Related Links
University of Notre Dame


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.